Cost Insights: Breaking Down Walgreens Boots Alliance, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses

Cost Dynamics: Walgreens vs. Supernus from 2014 to 2023

__timestampSupernus Pharmaceuticals, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 2014575800054823000000
Thursday, January 1, 2015842300076691000000
Friday, January 1, 20161198600087477000000
Sunday, January 1, 20171521500089052000000
Monday, January 1, 201815356000100745000000
Tuesday, January 1, 20191666000091915000000
Wednesday, January 1, 20205245900095905000000
Friday, January 1, 202175061000104442000000
Saturday, January 1, 202287221000104437000000
Sunday, January 1, 202383779000112009000000
Monday, January 1, 2024121134000000
Loading chart...

Unveiling the hidden dimensions of data

Unveiling Cost Dynamics: Walgreens Boots Alliance vs. Supernus Pharmaceuticals

In the ever-evolving landscape of the pharmaceutical and retail sectors, understanding cost structures is pivotal. Walgreens Boots Alliance, Inc., a retail giant, and Supernus Pharmaceuticals, Inc., a niche player, present contrasting cost narratives from 2014 to 2023. Walgreens consistently reported a cost of revenue exceeding $54 billion annually, peaking at $112 billion in 2023, reflecting its expansive retail operations. In contrast, Supernus, with a more focused pharmaceutical approach, saw its costs rise from $5.8 million in 2014 to $87 million in 2022, marking a staggering 1,400% increase. This divergence highlights the scale and operational differences between a global retailer and a specialized pharmaceutical firm. Notably, 2024 data for Supernus is missing, indicating potential reporting delays or strategic shifts. These insights underscore the importance of cost management in sustaining competitive advantage in diverse market environments.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025